PATENT CLAIM ANALYSIS

Application Number: 15977772
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "300000"]

Abstract:
Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Claim (Index 5):
The method of  claim 2 , wherein the one or more additional therapeutic agents is a tyrosine kinase inhibitor selected from the group consisting of apatinib, tivozanib, axitinib, vargatef, afatinib, brivanib alaninate, cediranib, chrysophanic acid, crenolanib, dovitinib dilactic acid, erlotinib hydrochloride, foretinib, gefitinib, imatinib, imatinib mesylate, lapatinib, linifanib, masitinib, motesanib, mubritinib, neratinib, pazopanib HCl, pelitinib, ponatinib, regorafenib, sorafenib tosylate, sunitinib malate, telatinib, vandetanib, vatalanib dihydrochloride, quizartinib, pexidartinib or cabozantinib.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 93.0
- Lexical Diversity: 1.61538
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15689931', '15269054', '13403394', '15160729', '15654538']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7776966741935114
- 35 USC 102 Novelty (BERT): 0.5811236487501784
- Combined Prediction Score: 0.7580393716491781
- Mean Citation Score: 358.29446
- Max Citation Score: 491.654
- Similarity Product: 394.1736915665865

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test